Clinical Policy: Pegfilgrastim (Neulasta, Neulasta Onpro), Pegfilgrastim-jmdb (Fulphila), Pegfilgrastim-cbqv (Udenyca), Pegfilgrastim-bmez (Ziextenzo), Pegfilgrastim-apgf (Nyvepria)

Reference Number: CP.PHAR.296
Effective Date: 12.01.16
Last Review Date: 02.21
Line of Business: Commercial, HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Pegfilgrastim (Neulasta®, Neulasta® Onpro®) and its biosimilars, pegfilgrastim-jmdb (Fulphila™), pegfilgrastim-cbqv (Udenyca™), pegfilgrastim-bmez (Ziextenzo™), and Pegfilgrastim-apgf (Nyvepria™) are leukocyte growth factors.

FDA Approved Indication(s)
Neulasta, Nyvepria, Fulphila, Udenyca, and Ziextenzo are indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia (FN).

Neulasta is also indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of acute radiation syndrome).

Limitation(s) of use: Neulasta, Nyvepria, Fulphila, Udenyca, and Ziextenzo are not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Neulasta, Neulasta Onpro, Nyvepria, Fulphila, Udenyca, and Ziextenzo are medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Chemotherapy-Induced Neutropenia (must meet all):
      1. Diagnosis of non-myeloid malignancy;
      2. Prescribed for use following myelosuppressive chemotherapy;
      3. One of the following (a, b, or c)
         1. Request is for treatment associated with Stage IV or metastatic cancer for a State with regulations against step therapy in advanced oncology settings (see Appendix E);
         2. For members age ≥ 18 years, both of the following (i and ii)
            a. Failure of Zaxrio, unless one of the following (1, 2, or 3):
1. Member has intolerance or contraindication to Zarxio;
2. Documentation of member’s inability to self-administer Zarxio due to both of the following (a and b):
   a) Lack of caregiver or support system for assistance with administration;
   b) Inadequate access to healthcare facility or home care interventions;
3. Member requires ≥ 10 doses of Zarxio;
   *Prior authorization may be required for Zarxio
b. One of the following (1, 2, or 3):
   1. Request is for Ziextenzo;
   2. If request is for a biosimilar pegfilgrastim product other than Ziextenzo (i.e., Fulphila, Udenyca, Nyvepria), member must use Ziextenzo, unless contraindicated or clinically significant adverse effects are experienced;
3. If request is for Neulasta or Neulasta Onpro, both of the following (a and b):
   a) Member must use Ziextenzo, unless contraindicated or clinically significant adverse effects are experienced;
   b) If member is unable to use Ziextenzo, member must use biosimilar pegfilgrastim products, unless clinically significant adverse effects are experienced or all are contraindicated;
   *Prior authorization may be required for Ziextenzo
3. For members age < 18 years, one of the following (1, 2, or 3):
   1. Request is for Ziextenzo;
   2. If request is for a biosimilar pegfilgrastim product other than Ziextenzo (i.e., Fulphila, Udenyca, Nyvepria), member must use Ziextenzo, unless contraindicated or clinically significant adverse effects are experienced;
3. If request is for Neulasta or Neulasta Onpro, both of the following (a and b):
   c) Member must use Ziextenzo, unless contraindicated or clinically significant adverse effects are experienced;
   d) If member is unable to use Ziextenzo, member must use biosimilar pegfilgrastim products, unless clinically significant adverse effects are experienced or all are contraindicated;
   *Prior authorization may be required for Ziextenzo
4. Confirmation that there is at least 12 days between pegfilgrastim dose and the next cycle of chemotherapy;
5. For members receiving palliative chemotherapy, provider attestation that chemotherapy dose reduction has been considered;
6. Dose does not exceed 6 mg (1 syringe) per chemotherapy cycle.

**Approval duration:**
- Medicaid/HIM – 6 months
- Commercial – 6 months or to the member’s renewal date, whichever is longer

**B. Acute Radiation Syndrome** (must meet all):
1. Prescribed for use following suspected or confirmed acute exposure to myelosuppressive doses of radiation;
2. One of the following (a, b, or c)
   1. Request is for treatment associated with Stage IV or metastatic cancer for a State with regulations against step therapy in advanced oncology settings *(see Appendix E)*;
   2. For members age ≥ 18 years, both of the following (i and ii)
      a. Failure of Zarxio, unless one of the following (1, 2, or 3):
         1. Member has intolerance or contraindication to Zarxio;
         2. Documentation of member’s inability to self-administer Zarxio due to both of the following (a and b):
            a) Lack of caregiver or support system for assistance with administration;
            b) Inadequate access to healthcare facility or home care interventions;
         3. Member requires ≥ 10 doses of Zarxio;
         *Prior authorization may be required for Zarxio*
      b. One of the following (1, 2, or 3):
         1. Request is for Ziextenzo;
         2. If request is for a biosimilar pegfilgrastim product other than Ziextenzo (i.e., Fulphila, Udenyca, Nyvepria), member must use Ziextenzo, unless contraindicated or clinically significant adverse effects are experienced;
         3. If request is for Neulasta or Neulasta Onpro, both of the following (a and b):
            a) Member must use Ziextenzo, unless contraindicated or clinically significant adverse effects are experienced;
            b) If member is unable to use Ziextenzo, member must use biosimilar pegfilgrastim products, unless clinically significant adverse effects are experienced or all are contraindicated;
         *Prior authorization may be required for Ziextenzo*
   3. For members age < 18 years, one of the following (1, 2, or 3):
      1. Request is for Ziextenzo;
      2. If request is for a biosimilar pegfilgrastim product other than Ziextenzo (i.e., Fulphila, Udenyca, Nyvepria), member must use Ziextenzo, unless contraindicated or clinically significant adverse effects are experienced;
      3. If request is for Neulasta or Neulasta Onpro, both of the following (a and b):
         a) Member must use Ziextenzo, unless contraindicated or clinically significant adverse effects are experienced;
         b) If member is unable to use Ziextenzo, member must use biosimilar pegfilgrastim products, unless clinically significant adverse effects are experienced or all are contraindicated;
         *Prior authorization may be required for Ziextenzo*
   3. Dose does not exceed two 6 mg doses administered one week apart.

**Approval duration:**
- Medicaid/HIM – 6 months
- Commercial – 6 months or to the member’s renewal date, whichever is longer

C. **Bone Marrow Transplantation (off-label)** (must meet all):
   1. Prescribed for one of the following (a or b):
CLINICAL POLICY
Pegfilgrastim, Pegfilgrastim-jmdb, Pegfilgrastim-cbqv, Pegfilgrastim-bmez, Pegfilgrastim-apgf

a. Supportive care post autologous hematopoietic cell transplantation;
b. Mobilization of peripheral-blood progenitor cells prior to autologous transplantation;

2. Failure of Leukine®, unless contraindicated or clinically significant adverse effects are experienced;
   *Prior authorization may be required for Leukine*

3. One of the following (a, b, or c)
a. Request is for treatment associated with Stage IV or metastatic cancer for a State with regulations against step therapy in advanced oncology settings (see Appendix E);
b. For members age ≥ 18 years, both of the following (i and ii)
i. Failure of Zarxio, unless one of the following (1, 2, or 3):
   1. Member has intolerance or contraindication to Zarxio;
   2. Documentation of member’s inability to self-administer Zarxio due to both of the following (a and b):
      a) Lack of caregiver or support system for assistance with administration;
      b) Inadequate access to healthcare facility or home care interventions;
   3. Member requires ≥ 10 doses of Zarxio;
      *Prior authorization may be required for Zarxio*
ii. One of the following (1, 2, or 3):
   1. Request is for Ziextenzo;
   2. If request is for a biosimilar pegfilgrastim product other than Ziextenzo (i.e., Fulphila, Udenyca, Nyvepria), member must use Ziextenzo, unless contraindicated or clinically significant adverse effects are experienced;
   3. If request is for Neulasta or Neulasta Onpro, both of the following (a and b):
      a) Member must use Ziextenzo, unless contraindicated or clinically significant adverse effects are experienced;
      b) If member is unable to use Ziextenzo, member must use biosimilar pegfilgrastim products, unless clinically significant adverse effects are experienced or all are contraindicated;
      *Prior authorization may be required for Ziextenzo*
c. For members age < 18 years, one of the following (1, 2, or 3):
   1. Request is for Ziextenzo;
   2. If request is for a biosimilar pegfilgrastim product other than Ziextenzo (i.e., Fulphila, Udenyca, Nyvepria), member must use Ziextenzo, unless contraindicated or clinically significant adverse effects are experienced;
   3. If request is for Neulasta or Neulasta Onpro, both of the following (a and b):
      a) Member must use Ziextenzo, unless contraindicated or clinically significant adverse effects are experienced;
      b) If member is unable to use Ziextenzo, member must use biosimilar pegfilgrastim products, unless clinically significant adverse effects are experienced or all are contraindicated;
      *Prior authorization may be required for Ziextenzo*
4. Request meets one of the following (a or b):
   a. Dose does not exceed 6 mg (1 syringe) per dose;
   b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Approval duration:**
- Medicaid/HIM – 6 months
- Commercial – 6 months or to the member’s renewal date, whichever is longer

**D. Other diagnoses/indications**
1. For members age ≥ 18 years, both of the following (a and b):
   a. Failure of Zarxio, unless one of the following (i, ii, or iii):
      i. Member has intolerance or contraindication to Zarxio;
      ii. Documentation of member’s inability to self-administer Zarxio due to both of the following (a and b):
         a) Lack of caregiver or support system for assistance with administration;
         b) Inadequate access to healthcare facility or home care interventions;
      iii. Member requires ≥ 10 doses of Zarxio;
      *Prior authorization may be required for Zarxio*
   b. One of the following (i, ii, or iii):
      i. Request is for Ziestenzo;
      ii. If request is for a biosimilar pegfilgrastim product other than Ziestenzo (i.e., Fulphila, Udenyca, Nyvepria), member must use Ziestenzo, unless contraindicated or clinically significant adverse effects are experienced;
      iii. If request is for Neulasta or Neulasta Onpro, both of the following (a and b):
         e) Member must use Ziestenzo, unless contraindicated or clinically significant adverse effects are experienced;
         f) If member is unable to use Ziestenzo, member must use biosimilar pegfilgrastim products, unless clinically significant adverse effects are experienced or all are contraindicated;
      *Prior authorization may be required for Ziestenzo*
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**II. Continued Therapy**
**A. All Indications in Section I** (must meet all):
1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy;
3. One of the following (a, b, or c)
   a. Request is for treatment associated with Stage IV or metastatic cancer for a State with regulations against step therapy in advanced oncology settings (*see Appendix E*);
b. For members age ≥ 18 years, both of the following (i and ii):
   i. Failure of Zarxio, unless one of the following (1, 2, or 3):
      1. Member has intolerance or contraindication to Zarxio;
      2. Documentation of member’s inability to self-administer Zarxio due to both of the following (a and b):
         a) Lack of caregiver or support system for assistance with administration;
         b) Inadequate access to healthcare facility or home care interventions;
      3. Member requires ≥ 10 doses of Zarxio;
         *Prior authorization may be required for Zarxio
   ii. One of the following (1, 2, or 3):
      1. Request is for Ziextenzo;
      2. If request is for a biosimilar pegfilgrastim product other than Ziextenzo (i.e., Fulphila, Udenyca, Nyvepria), member must use Ziextenzo, unless contraindicated or clinically significant adverse effects are experienced;
      3. If request is for Neulasta or Neulasta Onpro, both of the following (a and b):
         a) Member must use Ziextenzo, unless contraindicated or clinically significant adverse effects are experienced;
         b) If member is unable to use Ziextenzo, member must use biosimilar pegfilgrastim products, unless clinically significant adverse effects are experienced or all are contraindicated;
         *Prior authorization may be required for Ziextenzo
   
   c. For members age < 18 years, one of the following (1, 2, or 3):
      1. Request is for Ziextenzo;
      2. If request is for a biosimilar pegfilgrastim product other than Ziextenzo (i.e., Fulphila, Udenyca, Nyvepria), member must use Ziextenzo, unless contraindicated or clinically significant adverse effects are experienced;
      3. If request is for Neulasta or Neulasta Onpro, both of the following (a and b):
         a) Member must use Ziextenzo, unless contraindicated or clinically significant adverse effects are experienced;
         b) If member is unable to use Ziextenzo, member must use biosimilar pegfilgrastim products, unless clinically significant adverse effects are experienced or all are contraindicated;
         *Prior authorization may be required for Ziextenzo

4. If request is for a dose increase, new dose does not exceed one of the following (a, b, or c):
   a. Chemotherapy-induced neutropenia: 6 mg (1 syringe) administered once per chemotherapy cycle;
   b. Acute radiation syndrome: two 6 mg doses administered one week apart;
   c. Bone marrow transplantation: 6 mg (1 syringe) per dose, or dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).

Approval duration:
Medicaid/HIM – 6 months
Commercial – 6 months or to the member’s renewal date, whichever is longer
B. Other diagnoses/indications (must meet 1 or 2):

1. For members age ≥ 18 years, both of the following (a and b)
   a. Failure of Zarxio, unless one of the following (i, ii, or iii):
      i. Member has intolerance or contraindication to Zarxio;
      ii. Documentation of member’s inability to self-administer Zarxio due to both of
          the following (a and b):
         a) Lack of caregiver or support system for assistance with administration;
         b) Inadequate access to healthcare facility or home care interventions;
      iii. Member requires ≥ 10 doses of Zarxio;
*Prior authorization may be required for Zarxio
   b. One of the following (i, ii, or iii):
      i. Request is for Ziextenzo;
      ii. If request is for a biosimilar pegfilgrastim product other than Ziextenzo (i.e.,
         Fulphila, Udenyca, Nyvepria), member must use Ziextenzo, unless
         contraindicated or clinically significant adverse effects are experienced;
      iii. If request is for Neulasta or Neulasta Onpro, both of the following (a and b):
         a) Member must use Ziextenzo, unless contraindicated or clinically
            significant adverse effects are experienced;
         b) If member is unable to use Ziextenzo, member must use biosimilar
            pegfilgrastim products, unless clinically significant adverse effects are
            experienced or all are contraindicated;
*Prior authorization may be required for Ziextenzo

2. Currently receiving medication via Centene benefit and documentation supports
   positive response to therapy.
   Approval duration: Duration of request or 6 months (whichever is less); or

3. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT
   specifically listed under section III (Diagnoses/Indications for which coverage is
   NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance
   marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

   A. Non-FDA approved indications, which are not addressed in this policy, unless there is
      sufficient documentation of efficacy and safety according to the off label use policies –
      CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and
      CP.PMN.53 for Medicaid, or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key
ANC: absolute neutrophil count             FDA: Food and Drug Administration
ASCO: American Society of Clinical Oncology FN: febrile neutropenia
CSFs: colony-stimulating factors            NCCN: National Comprehensive Cancer Network
Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
</table>
| Neupogen® (filgrastim), Zarfio® (filgrastim-sndz), Granix® (tbo-filgrastim), Nivestym® (filgrastim-aafi) | Supportive care post autologous hematopoietic cell transplantation  
10 mcg/kg IV or SC infusion QD  
Mobilization of peripheral-blood progenitor cells prior to autologous transplantation  
10 mcg/kg SC bolus or continuous infusion QD | 10 mcg/kg/day |
| Leukine® (sargramostim)    | Supportive care post autologous hematopoietic cell transplantation  
250 mcg/m²/day IV  
Mobilization of peripheral-blood progenitor cells prior to autologous transplantation  
250 mcg/m²/day IV or SC QD | 500 mcg/m²/day  
250 mcg/m²/day |

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): history of serious allergic reactions to human granulocyte colony-stimulating factors such as pegfilgrastim or filgrastim products
- Boxed warning(s): none reported

Appendix D: General Information

- Neutropenia is defined as an absolute neutrophil count (ANC) of < 500 neutrophils/mcL or an ANC of < 1,000 neutrophils/mcL and a predicted decline to ≤ 500 neutrophils/mcL over the next 48 hours. Neutropenia can progress to FN, defined as a single temperature of ≥ 38.8 C orally or ≥ 38.0 C over 1 hour.
- The development of FN is a common dose-limiting toxicity of many chemotherapy regimens. This risk is directly related to the intensity of the chemotherapy regimen. Chemotherapy regimens that have an incidence of FN greater than 20% in clinical trials in chemotherapy naïve patients are considered by the National Comprehensive Cancer Network (NCCN) panel at high risk. Prophylaxis with myeloid growth factors is recommended at this level of risk (category 1 recommendation). NCCN Compendium recommend prophylaxis be considered in intermediate-risk (10-20% overall risk of FN) patients (category 2A recommendation). In addition to chemotherapy regimens, other risk factors such as: treatment-related, patient related, cancer-related, and co-morbidities have also been associated with an increased risk of FN. Therefore, the type of chemotherapy regimen is only one component of the risk assessment.
• Harvesting of peripheral blood stem cells prior to autologous stem-cell transplantation has a recommendation of Class IIa in DRUGDEX.
• The NCCN Compendium recommends Neulasta for supportive care post autologous hematopoietic cell transplant (category 2A).
• According to the ASCO, 2006 Clinical Practice Guideline for the Use of White Blood Cell Growth Factors, dose reduction or delay remains an appropriate strategy for the palliative treatment of cancer, as there is no evidence that dose maintenance or escalation improves clinically important outcomes in this setting. The 2015 updates to this guideline found no new data supporting the use of colony-stimulating factors (CSFs) to maintain dose-intensity in the treatment of metastatic disease, and the review found no demonstrable benefit in the use of myeloid growth factors to in patients with metastatic lung, small-cell lung, colorectal, hormone-refractory prostate, or breast cancer. To date, there have been no improvements in disease-free or OS reported for any common cancer with the use of CSFs to maintain dose-intensity, instead of dose reduction. The ASCO Panel recognizes that there may be individual patients who will not tolerate effective doses of chemotherapy without CSFs. Medical Oncologists making the decision to use prophylactic MGFs, or not, may need to consider not only the optimal chemotherapy regimen, but also the individual member risk factors and the intention of treatment; that is, curative, prolongation of life, or symptom control and palliation.

Appendix E: States with Regulations against Redirections in Stage IV or Metastatic Cancer

<table>
<thead>
<tr>
<th>State</th>
<th>Step Therapy Prohibited?</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>FL</td>
<td>Yes</td>
<td>For stage 4 metastatic cancer and associated conditions.</td>
</tr>
<tr>
<td>GA</td>
<td>Yes</td>
<td>For stage 4 metastatic cancer. Redirection does not refer to review of medical necessity or clinical appropriateness.</td>
</tr>
<tr>
<td>IA</td>
<td>Yes</td>
<td>For standard of care stage 4 cancer drug use, supported by peer-reviewed, evidence-based literature, and approved by FDA.</td>
</tr>
<tr>
<td>LA</td>
<td>Yes</td>
<td>For stage 4 advanced, metastatic cancer or associated conditions. Exception if “clinically equivalent therapy, contains identical active ingredient(s), and proven to have same efficacy.”</td>
</tr>
<tr>
<td>OH</td>
<td>Yes</td>
<td><em>Applies to Commercial and HIM requests only</em> For stage 4 metastatic cancer and associated conditions</td>
</tr>
<tr>
<td>PA</td>
<td>Yes</td>
<td>For stage 4 advanced, metastatic cancer</td>
</tr>
<tr>
<td>TN</td>
<td>Yes</td>
<td>For advanced metastatic cancer and associated conditions</td>
</tr>
<tr>
<td>TX</td>
<td>Yes</td>
<td>For stage 4 advanced, metastatic cancer and associated conditions</td>
</tr>
</tbody>
</table>

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pegfilgrastim (Neulasta), pegfilgrastim-jmdb (Fulphila),</td>
<td>Myelosuppressive chemotherapy</td>
<td>6 mg administered SC once per chemotherapy cycle. Do not administer between 14 days before and 24 hours after</td>
<td>6 mg/dose</td>
</tr>
</tbody>
</table>
CLINICAL POLICY
Pegfilgrastim, Pegfilgrastim-jmdb, Pegfilgrastim-cbqv, Pegfilgrastim-bmez, Pegfilgrastim-apgf

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>pegfilgrastim-cbqv (Udenyca), pegfilgrastim-bmez (Ziextenzo), pegfilgrastin-apgf (Nyvepria)</td>
<td>administration of cytotoxic chemotherapy. Weight based dosing for pediatric patients &lt; 45 kg</td>
<td>Two doses, 6 mg each, administered SC one week apart. Administer the first dose as soon as possible after suspected or confirmed exposure to myelosuppressive doses of radiation, and a second dose one week after. Weight based dosing for pediatric patients &lt; 45 kg</td>
<td>6 mg/dose</td>
</tr>
<tr>
<td>Pegfilgrastim (Neulasta)</td>
<td>Members acutely exposed to myelosuppressive doses of radiation</td>
<td>Two doses, 6 mg each, administered SC one week apart. Administer the first dose as soon as possible after suspected or confirmed exposure to myelosuppressive doses of radiation, and a second dose one week after. Weight based dosing for pediatric patients &lt; 45 kg</td>
<td>6 mg/dose</td>
</tr>
</tbody>
</table>

VI. Product Availability

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pegfilgrastim (Neulasta)</td>
<td>Injection: 6 mg/0.6 mL solution in a single-dose prefilled syringe for manual use only</td>
</tr>
<tr>
<td></td>
<td>Injection: 6 mg/0.6 mL solution in a single-dose prefilled syringe co-packaged with the on-body injector</td>
</tr>
<tr>
<td>Pegfilgrastin-apgf (Nyvepria)</td>
<td>Injection: 6 mg/0.6 mL solution in a single-dose prefilled syringe for manual use only</td>
</tr>
<tr>
<td>Pegfilgrastim-jmdb (Fulphila)</td>
<td>Injection: 6 mg/0.6 mL solution in a single-dose prefilled syringe for manual use only</td>
</tr>
<tr>
<td>Pegfilgrastim-cbqv (Udenyca)</td>
<td>Injection: 6 mg/0.6 mL solution in a single-dose prefilled syringe for manual use only</td>
</tr>
<tr>
<td>Pegfilgrastim-bmez (Ziextenzo)</td>
<td>Injection: 6 mg/0.6 mL solution in a single-dose prefilled syringe for manual use only</td>
</tr>
</tbody>
</table>

VII. References

Coding Implications
Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J2505</td>
<td>Injection, pegfilgrastim, 6 mg</td>
</tr>
<tr>
<td>Q5111</td>
<td>Injection, pegfilgrastim-cbqv, biosimilar, (Udenyca), 0.5 mg</td>
</tr>
<tr>
<td>Q5108</td>
<td>Injection, pegfilgrastim-jmdb, biosimilar, (Fulphila), 0.5 mg</td>
</tr>
<tr>
<td>Q5120</td>
<td>Injection, pegfilgrastim-bmez, biosimilar, (Zieextenzo), 0.5 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Updated template and references. Removed off-label use.</td>
<td>08.16.17</td>
<td>11.17</td>
</tr>
<tr>
<td>3Q 2018 annual review: policies combined for Medicaid and Commercial lines of business; added HIM line of business; added off-label indications for mobilization of peripheral-blood progenitor cells and supportive care post autologous hematopoietic cell transplantation with redirection to FDA approved treatments Leukine and Neupogen, Granix, or Zarxio; references reviewed and updated.</td>
<td>05.08.18</td>
<td>08.18</td>
</tr>
<tr>
<td>Newly FDA-approved biosimilar added: Fulphila; references reviewed and updated.</td>
<td>07.31.18</td>
<td>02.19</td>
</tr>
<tr>
<td>Newly FDA-approved biosimilar added: Udenyca.</td>
<td>03.21.19</td>
<td></td>
</tr>
<tr>
<td>Reviews, Revisions, and Approvals</td>
<td>Date</td>
<td>P&amp;T Approval Date</td>
</tr>
<tr>
<td>--------------------------------------------------------------------------------------------------</td>
<td>---------</td>
<td>-------------------</td>
</tr>
<tr>
<td>3Q 2019 annual review: added Nivestym to list of filgrastim products required for bone marrow</td>
<td>05.15.19</td>
<td>08.19</td>
</tr>
<tr>
<td>transplant indication, updated HCPCS coding table to include biosimilar products; references</td>
<td></td>
<td></td>
</tr>
<tr>
<td>reviewed and updated.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>For chemotherapy-induced neutropenia and acute radiation syndrome, added redirection to Zarxio;</td>
<td>10.08.19</td>
<td>11.19</td>
</tr>
<tr>
<td>For bone marrow transplant narrowed previous redirection to Neupogen, Zarxio, Granix, or Nivestym</td>
<td></td>
<td></td>
</tr>
<tr>
<td>to Zarxio only. For Zarxio redirection added the following scenarios where redirection is not</td>
<td></td>
<td></td>
</tr>
<tr>
<td>required: a. Member has intolerance or contraindication to Zarxio; b. Documentation of member’s</td>
<td></td>
<td></td>
</tr>
<tr>
<td>inability to self-administer Zarxio due to both of the following (i and ii): i. Lack of</td>
<td></td>
<td></td>
</tr>
<tr>
<td>caregiver or support system for assistance with administration; ii. Inadequate access to</td>
<td></td>
<td></td>
</tr>
<tr>
<td>healthcare facility or home care interventions; c. Member requires ≥ 10 doses of Zarxio. For</td>
<td></td>
<td></td>
</tr>
<tr>
<td>chemotherapy-induced neutropenia added requirement for members receiving palliative</td>
<td></td>
<td></td>
</tr>
<tr>
<td>chemotherapy, provider’s attestation that chemotherapy dose reduction has been considered.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Appendix D updated to include ASCO recommendations related to consideration of chemotherapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>dose reduction.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RT4: added Ziextenzo to policy.</td>
<td>02.12.20</td>
<td></td>
</tr>
<tr>
<td>Added requirement for redirection to Zarxio to Section II for continued therapy requests;</td>
<td>04.20.20</td>
<td>05.20</td>
</tr>
<tr>
<td>allowed by-passing of redirection if state regulations do not allow step therapy in Stage IV or</td>
<td></td>
<td></td>
</tr>
<tr>
<td>metastatic cancer settings.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Added redirection to a biosimilar pegfilgrastim if member is unable to use Zarxio; revised 11.19</td>
<td>07.30.20</td>
<td></td>
</tr>
<tr>
<td>update revision log to remove that redirection change to Zarxio came from SDC.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3Q 2020 annual review: no significant changes; references reviewed and updated.</td>
<td>04.30.20</td>
<td>08.20</td>
</tr>
<tr>
<td>RT4: added new biosimilar Nyvepria to policy; added redirection to a biosimilar pegfilgrastim</td>
<td>08.20.20</td>
<td></td>
</tr>
<tr>
<td>for all indications if member is unable to use Zarxio, including Section II continued therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Per September SDC and prior clinical guidance, added redirection to Ziextenzo for Fulphila,</td>
<td>09.21.20</td>
<td></td>
</tr>
<tr>
<td>Neulasta, Nyvepria, or Udenyca requests.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Removed AR from appendix E (“For metastatic cancer, unless the preferred drug is consistent</td>
<td></td>
<td></td>
</tr>
<tr>
<td>with “best practices” (1) used for treatment under (A) FDA-approved indication, or (B) National</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comprehensive Cancer Network Drugs &amp; Biologics Compendium; or (2) using evidence-based, peer-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>reviewed, recognized medical literature. Note – may not require step therapy a second time for</td>
<td></td>
<td></td>
</tr>
<tr>
<td>same Rx drug”) to minimize misinterpretation.</td>
<td>11.16.20</td>
<td></td>
</tr>
</tbody>
</table>
### Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Description</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clarified that redirections to Ziextenzo apply to Neulasta, Neulasta Onpro, and all non-preferred pegfilgrastim products.</td>
<td>01.26.21</td>
<td></td>
</tr>
<tr>
<td>Add requirement for confirmation that there is at least 12 days between pegfilgrastim dose and the next cycle of chemotherapy; references to HIM.PHAR.21 revised to HIM.PA.154.</td>
<td>10.26.20</td>
<td>02.21</td>
</tr>
<tr>
<td>Updated appendix E to include Ohio.</td>
<td>02.08.21</td>
<td></td>
</tr>
<tr>
<td>Clarified redirection language to indicate Zarxio must be used, followed by Ziextenzo, followed by other pegfilgrastim biosimilars, followed by Neulasta or Neulasta Onpro. Updated GA language in appendix E.</td>
<td>03.02.21</td>
<td></td>
</tr>
<tr>
<td>Ad Hoc update: applied redirection language to other diagnoses/indications</td>
<td>03.15.21</td>
<td></td>
</tr>
</tbody>
</table>

### Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.
This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note: For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.